Physician profile
Peter A Lee
NPI 1982857462
$2,297.73
in general payments reported to CMS, 2019-2025
16 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $13.80 · 2021: $134 · 2022: $464 · 2023: $404 · 2024: $480 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Education: $21.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.54 |
| Education | $21.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $780.14 | 2021-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $461.68 | 2021-2024 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $153.46 | 2022-2024 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $140.53 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $128.11 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $121.67 | 2023-2025 | |
| Amgen INC. | $100.50 | 2022-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $78.68 | 2025 | |
| Aurinia Pharma U.S., INC. | $74.69 | 2022-2023 | Lupkynis |
| Ardelyx, INC. | $63.88 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.61 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $51.85 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $22.91 | 2023 | |
| Daiichi Sankyo INC. | $22.90 | 2022 | |
| Opko Pharmaceuticals, LLC | $21.87 | 2025 | Rayaldee |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.25 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.